MediciNova Secures U.S. Patent Allowance for Ibudilast–Anti-PD-1 Combination in Glioblastoma
核心洞察
MediciNova received a Notice of Allowance from the USPTO for a patent covering ibudilast (MN-166) combined with anti-PD-1 (搜索) immune checkpoint inhibitors for glioblastoma (搜索) treatment.
The allowed claims encompass multiple anti-PD-1 (搜索) antibodies and broad treatment parameters including dosing regimen, route of administration, dose levels, and duration of therapy.
Once issued, the patent is expected to expire no earlier than September 2042, strengthening the company's intellectual property position in oncology.
MediciNova, Inc., a clinical-stage biopharmaceutical company traded on the NASDAQ Global Market and the Tokyo Stock Exchange, announced on June 8, 2026 that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of ibudilast (MN-166) in combination with an anti-PD-1 (搜索) immune checkpoint inhibitor for the treatment of glioblastoma (搜索). The patent allowance is expected to further strengthen the intellectual property foundation supporting the company's combination therapy development strategy in oncology.
Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, stated, "This Notice of Allowance further strengthens our intellectual property estate for MN-166 in glioblastoma (搜索) and supports continued evaluation of ibudilast-based combination strategies in this aggressive malignancy. The allowed claims encompass use in combination with anti-PD-1 (搜索) antibodies across multiple treatment parameters, including dosing regimen, route of administration, and duration of therapy, which we believe is strategically important as we continue to assess the potential clinical utility of MN-166 in oncology."
Matsuda further emphasized the clinical context driving the development program: "Given the persistent unmet need in glioblastoma (搜索), we believe this patent position provides important support for the ongoing development of rational combination approaches intended to improve therapeutic outcomes."
Patent Scope and Duration
Once issued, the patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 (搜索) antibodies but also a broad range of treatment conditions, including duration of administration, dosing frequency, route of administration, dose levels, and dosing schedules. This breadth of coverage provides MediciNova with substantial flexibility as it continues to evaluate the clinical utility of MN-166 in oncology settings.
MN-166 (Ibudilast) Mechanism and Pipeline
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4 (搜索)) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF (搜索)). The compound is in late-stage clinical development for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). Beyond glioblastoma (搜索), ibudilast is also in development for Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. The compound has additionally been evaluated in patients at risk for developing acute respiratory distress syndrome (ARDS).
MediciNova's lead asset, MN-166, is currently in Phase 3 trials for ALS and DCM and is Phase 3-ready for progressive MS. The company is also evaluating MN-166 in Phase 2 trials for Long COVID and substance dependence. A second pipeline compound, MN-001 (tipelukast), has been evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF), with an additional Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) ongoing.
Strategic Implications
The patent allowance represents a significant step in MediciNova's efforts to build a robust intellectual property portfolio around ibudilast-based combination regimens in glioblastoma (搜索), a disease with notoriously limited treatment options. By securing claims that span multiple anti-PD-1 (搜索) antibodies and diverse treatment parameters, the company positions itself to explore rational combination approaches that may address the persistent therapeutic challenges in this aggressive brain malignancy.